Stevanato Group S.p.A. (STVN)
| Market Cap | 4.27B -24.9% |
| Revenue (ttm) | 1.42B +6.6% |
| Net Income | 159.42M -0.2% |
| EPS | 0.58 +0.1% |
| Shares Out | 273.13M |
| PE Ratio | 27.02 |
| Forward PE | 22.65 |
| Dividend | $0.06 (0.39%) |
| Ex-Dividend Date | Jun 11, 2026 |
| Volume | 702,634 |
| Open | 15.90 |
| Previous Close | 15.93 |
| Day's Range | 15.35 - 16.15 |
| 52-Week Range | 12.05 - 24.01 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | 19.46 (+24.35%) |
| Earnings Date | Nov 3, 2026 |
About STVN
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injector... [Read more]
Financial Performance
In 2025, Stevanato Group's revenue was 1.19 billion, an increase of 7.45% compared to the previous year's 1.10 billion. Earnings were 139.84 million, an increase of 18.73%.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for STVN stock is "Buy." The 12-month stock price target is $19.46, which is an increase of 24.35% from the latest price.
News
Stevanato Group Transcript: Jefferies Global Healthcare Conference
Q3 organic growth was 8%, with a 27% adjusted EBITDA margin as high-value capacity ramped. A temporary GLP-1 customer headwind resets 2027 growth expectations to low single digits, while margin expansion and higher free cash flow remain targets.
Stevanato Group to Participate in Upcoming Investor Conferences
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $STVN--STVN Investors Have Opportunity to Join Stevanato Group S.p.A. Fraud Investigation with SBS Law.
Lost Money on Stevanato Group S.p.A. Shares? The Law Offices of Frank R.
LOS ANGELES--(BUSINESS WIRE)--Stevanato Group S.p.A. ("Stevanato" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced i...
Did You Lose Money on Stevanato Group S.p.A. Stock? The Law Offices of Howard G.
BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Stevanato Group S.p.A. ("Stevanato" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith...
Stevanato downgraded to Market Perform from Outperform at William Blair
William Blair analyst Matt Larew downgraded Stevanato (STVN) to Market Perform from Outperform. The firm says 2027 has turned into a transition year for Stevanato due to lower than expected…
Stevanato Group (STVN) Shareholder Investigation Following Stock Decline – Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of Stevanato Group (STVN) investors following the Company's stock price decline
Stevanato Group price target lowered to $16 from $23 at UBS
UBS lowered the firm’s price target on Stevanato Group (STVN) to $16 from $23 and keeps a Neutral rating on the shares.
Stevanato Group price target lowered to $20 from $26 at Citi
Citi lowered the firm’s price target on Stevanato Group (STVN) to $20 from $26 and keeps a Buy rating on the shares.
Stevanato Group S.p.A. Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Stevanato Group S.p.A.
STVN shares fell on November 3, 2026, as the market reacted to a lower GLP-1 revenue outlook in Stevanato Group's pre-market third-quarter results, the issue previews had flagged as the quarter's key ...
Stevanato Group price target lowered to $25 from $32 at KeyBanc
KeyBanc lowered the firm’s price target on Stevanato Group (STVN) to $25 from $32 and keeps an Overweight rating on the shares.
Stevanato Group price target lowered to $20 from $25 at TD Cowen
TD Cowen lowered the firm’s price target on Stevanato Group (STVN) to $20 from $25 and keeps a Buy rating on the shares.
Stevanato Stock (STVN) Plummets on Mixed Q3 Earnings and a Stark Guidance Warning
Stevanato stock fell hard on Tuesday after the company’s latest earnings report included mixed results and lackluster guidance.
Stevanato Group falls -24.0%
Stevanato Group (STVN) is down -24.0%, or -$4.74 to $15.00.
Stevanato Group reports Q3 EPS EUR 0.15 vs EUR 0.13 last year
Reports Q3 revenue EUR 326.1M vs EUR 303.2M last year. Franco Stevanato, Chairman and Chief Executive Officer, commented, “Third-quarter results were in line with our expectations, with 8% organic rev...
Stevanato Group reaffirms FY26 adjusted EPS view EUR 0.60 – EUR 0.62
Reaffirms FY26 revenue view of EUR 1.26B – EUR 1.28B. Franco Stevanato, Chairman and Chief Executive Officer, commented, “The demand environment for injectable biologics remains structurally strong, s...
Stevanato Group falls -27.6%
Stevanato Group (STVN) is down -27.6%, or -$5.44 to $14.30.
Stevanato Group Earnings Call Transcript: Q3 2026
Q3 revenue rose 8% as BDS growth offset engineering weakness, and adjusted EBITDA margin expanded to 27.2%. A single customer’s Nexa syringe volume reduction is expected to temper 2027 growth, with most capacity being backfilled.
Stevanato Group Earnings release: Q3 2026
Stevanato Group released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Stevanato Group Slides: Q3 2026
Stevanato Group has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Stevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...
Stevanato announces collaboration with Aptar Pharma
Stevanato Group (STVN) announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical compan...
Aptar Pharma enters collaboration with Stevanato Group
Aptar Pharma, part of AptarGroup (ATR) announced a collaboration with Stevanato Group (STVN) to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech...
Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN) (the “Company”), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical...
Stevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,...